Equillium, Inc. (NASDAQ:EQ) Sees Large Increase in Short Interest

Equillium, Inc. (NASDAQ:EQ) was the target of a large growth in short interest in January. As of January 31st, there was short interest totalling 93,300 shares, a growth of 245.6% from the January 15th total of 27,000 shares. Based on an average daily volume of 771,800 shares, the days-to-cover ratio is presently 0.1 days. Currently, 0.5% of the shares of the stock are sold short.

Institutional Inflows and Outflows

An institutional investor recently bought a new position in Equillium stock. Takeda Pharmaceutical Co. Ltd. purchased a new position in Equillium, Inc. (NASDAQ:EQ) in the 4th quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The fund purchased 1,824,977 shares of the company’s stock, valued at approximately $1,369,000. Equillium comprises about 5.2% of Takeda Pharmaceutical Co. Ltd.’s investment portfolio, making the stock its 4th largest position. Takeda Pharmaceutical Co. Ltd. owned approximately 5.15% of Equillium at the end of the most recent reporting period. Institutional investors and hedge funds own 27.05% of the company’s stock.

Equillium Stock Performance

Equillium stock traded down $0.01 during midday trading on Wednesday, hitting $0.88. 193,832 shares of the company’s stock were exchanged, compared to its average volume of 1,626,384. The company has a market cap of $31.11 million, a P/E ratio of -6.27 and a beta of 1.79. The stock has a 50-day moving average price of $0.70 and a two-hundred day moving average price of $0.81. Equillium has a 52-week low of $0.49 and a 52-week high of $3.25.

Equillium Company Profile

Equillium, Inc, a clinical-stage biotechnology company, develops and sells products to treat severe autoimmune and inflammatory, or immuno-inflammatory disorders with unmet medical need. The company's lead product candidate is itolizumab (EQ001), a first-in-class monoclonal antibody that targets the immune checkpoint receptor CD6, which is in Phase III clinical trials for the treatment of acute graft-versus-host disease; completed Phase I clinical trial for the treatment of ulcerative colitis; and Phase I clinical trial for the treatment of lupus nephritis.